ABSTRACT
Sumatriptan pharmacotherapy has been commonly associated with chest pain; dizziness; fatigue; feeling of heaviness; neck stiffness; pressure sensation; taste disturbances after intranasal administration; transient local burning sensation, erythema, or pain at the injection site after subcutaneous injection; and weakness. In the absence of such data, sumatriptan overdosage should be treated as a medical emergency requiring symptomatic medical support of body systems with attention to increasing sumatriptan elimination. Avoid prescribing sumatriptan pharmacotherapy to women who are pregnant. If sumatriptan pharmacotherapy is required, advise patients of potential benefits and possible risks to themselves and the embryo, fetus, or neonate. The sumatriptan injectable is for subcutaneous use only. Never inject sumatriptan intravenously. A burning sensation commonly is experienced at the subcutaneous injection site of sumatriptan. The bioavailability of sumatriptan following oral ingestion or intranasal insufflation is low, primarily due to significant first-pass hepatic metabolism.
